Previous Close | 0.7574 |
Open | 0.5600 |
Bid | 0.4349 x 100 |
Ask | 0.4952 x 100 |
Day's Range | 0.6601 - 0.8800 |
52 Week Range | 0.4050 - 13.1000 |
Volume | |
Avg. Volume | 1,371,192 |
Market Cap | 15.103M |
Beta (5Y Monthly) | -0.00 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0000 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
KLTO strengthens team with industry veteran and is poised to accelerate the development of its therapeutic candidatesNEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases, today announced the appointment of Peter Moriarty, Co-Founder of Shire Pharmaceuticals, as its Chief Operating Officer (COO). Dr. Joseph Sinkule, Chairman, CEO, and Founder of Klotho Neurosc
Renowned Biotech Leader to Contribute Expertise in Neuroscience and Therapeutics DevelopmentNEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative diseases and promoting healthy longevity, is proud to announce that Dr. Robert Langer, co-founder of Moderna, has joined its Scientific Advisory Board. In addition to lending his world-class scientific expertise to gui